Moxifloxacin (Avelox®): a novel fluoroquinolone with a broad spectrum of activity

Bibliography

• Dalhoff A, Petersen U, Endermann R.hi vitro activity of BAY 12–8039, a new 8-methoxyquinolone. Chemotherapy 42, 410–425 (1996).
   Google Scholar
• Iannini PB, Kubin R, Reiter C. Over 10 million patients uses: an update on the safety profile of oral moxifloxacin. Am. Soc. Mcrobiol. CA, USA 346 (2002).
   Google Scholar
• Chen DK, McGeer A, de Azavedo JC, Low DE, The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada. N Engl. Merl 341,233–239 (1999).
   Google Scholar
• Ho PL, Yung RVV, Tsang DN, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.1 Antimiavb. Chemother. 48,659–665 (2001).
   PubMed Web of Science ®Google Scholar
• Goldsmith CE, Moore JE, Murphy PG, Ambler JE. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.Antimiavb. Chemother. 41,420–421 (1998).
   PubMed Web of Science ®Google Scholar
• Resistance of Streptococcus pneumoniae to fluoroquinolones: United States, 1995-1999. MMWR Morb. Mortal. Wkly Rep. 50,800–804 (2001).
   PubMedGoogle Scholar
• Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg. Infect. Dis. 9,1–9 (2003).
   PubMed Web of Science ®Google Scholar
• Kishh R, Takei M, Fukuda H, Hayashi K, Hosaka M. Contribution of the 8-methoxy group to the activity of gatifloxacin against Type II topoisomerases of Streptococcus pneumoniae. Antimiavb. Agents Chemother. 47,77-81 (2003).
   Google Scholar
• Marutani K, Matsumoto M, Otabe Y, et al Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimiavb. Agents Chemother 37, 2217–2223 (1993).
   PubMed Web of Science ®Google Scholar
• Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Stmptococcus pneumordae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin and trovafloxacin efflux. Antimiavb. Agents Chemother. 44,798-801 (2000). iiBearden DT, Danziger LH. Mechanism of action of and resistance to quinolones. Pharmacotherapy21, S224-S232 (2001).
   Google Scholar
• Hooper DC. Bacterial topoisomerases, anti-topoisomerases and anti-topoisomerase resistance. Clin. Infect. Dis. 27\(Suppl. 1), S54-S63 (1998).
   PubMedGoogle Scholar
• •Good discussion of the fluoroquinolone class and the emergence of resistance.
   Google Scholar
• Drlica K, Malik M. Fluoroquinolones:action and resistance. CUI7: Top. Med Chem. 3,249–282 (2003).
   PubMed Web of Science ®Google Scholar
• Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7,337–341 (2001).
   PubMed Web of Science ®Google Scholar
• Jones ME, Sahm DF, Martin N, et al. Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Stmptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimiavb. Agents Chemother 44, 462–466 (2000).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Stceptococcu s pneumoniae in the United States. N. Engl. Med 343,1917–1924 (2000).
   PubMed Web of Science ®Google Scholar
• Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of BAY 12-8039 on Gram-positive and Gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect. Antimiavb. Agents Chemother 41, 1377–1379 (1997).
   PubMed Web of Science ®Google Scholar
• Wise R, Andrews JM, Marshall G, Hartman G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimiavb. Agents Chemother. 43,1508–1510 (1999).
   PubMed Web of Science ®Google Scholar
• Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimiavb. Agents Chemother. 42,2060–2065 (1998).
   PubMed Web of Science ®Google Scholar
• Muller M, Stass H, Brunner M, Moller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimiavb. Agents Chemother 43,2345–2349 (1999).
   PubMed Web of Science ®Google Scholar
• Pascual A, Garcia I, Ballesta S, Perea EJ. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimiavb. Agents Chemother 43,12–15 (1999).
   PubMed Web of Science ®Google Scholar
• Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy20, 245–256 (2000).
   Google Scholar
• •A detailed discussion of pharrnacoldnetic-pharmacodynamic characteristics.
   Google Scholar
• Hamamoto K, Shimizu T, Fujimoto N, Zhang Y, Arai S. In vitro activities of moxifloxacin and other fluoroquinolones against 4coplasma pneumoniae. Antimiavb. Agents Chemother 45, 1908–1910 (2001).
   Google Scholar
• Roblin PM, Hammerschlag MR In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimiavb. Agents Chemother. 42,951–952 (1998).
   PubMed Web of Science ®Google Scholar
• Marivitlles M, Kunkel M. Moxifloxacin provides rapid clinical and bactriological resolution of acute exacerbation of chronic bronchitis (AECB): a review of the literature. 10th International Soc. Infectious Dis. (2002).
   Google Scholar
• •Highlights the benefits in the treatment of acute exacerbation of chronic bronchitis.
   Google Scholar
• Boswell FJ, Andrews JM, Jevons G, Wise R. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. Antimiavb. Chemother. 50,495–502 (2002).
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A, et al Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am. j Respir. Cat. Cam Med. 163,1730–1754 (2001).
   PubMed Web of Science ®Google Scholar
• Landen H, Moller M, Tillotson GS, Kubin R, Hoffken G. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. j Int. Med. Res. 29,51–60 (2001).
   PubMed Web of Science ®Google Scholar
• Gehanno P, Darantiere S, Dubreuil C, et al A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. j Antimiavb. Chemother. 49,821–826 (2002).
   PubMed Web of Science ®Google Scholar
• Krasemann C, Meyer J. Moxifloxacin (MFX) in acute sinusitis (AS): a bacteriological and clinical meta-analysis. In: Programs and Abstracts of the 9th European Congress of Clinical Microbiology and Infectious Diseases. Taufkirchen, Germany, 139 (1999) (Abstract P204).
   Google Scholar
• Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership. Otolaryngol Head Neck Surg. 123,5–31 (2000).
   PubMed Web of Science ®Google Scholar
• Blondeau JM. The role of fluoroquinolones in skin and skin structure infections. Am. j Clin. Dermatol 3,37–46 (2002).
   PubMedGoogle Scholar
• Behra-Miellet J, Dubreuil L, Jumas-Bilak E. Anti-anaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and fi-lactams. Int. Antimicrob. Agents 20,366–374 (2002).
   PubMed Web of Science ®Google Scholar
• Sobottka I, Cachovan G, Sturenburg E, etal In vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses. Antimiavb. Agents Chemother. 46, 4019–4021 (2002).
   PubMed Web of Science ®Google Scholar
• Hedberg M, Nord CE. Antimicrobial susceptibility of Bacteroides hvgilis group isolates in Europe. Clin. Mcrobiol Infect. 9, 475–488 (2003).
   PubMed Web of Science ®Google Scholar
• Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of mycobacterium tuberculosis. Antimiavb. Agents Chemother. 47,653–657 (2003).
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. A117. I Respir. Cat. Care Med 167,603–662(2003).
   PubMed Web of Science ®Google Scholar
• Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. j Chemother. 15, 66–70 (2003).
   Web of Science ®Google Scholar
• Gomez-Rodriguez J, Ruiz-Serrano M, Cuevas O, et al. Comparative in vitro activity of moxifloxacin and linezolid with other agents against significant rapidly growing mycobacteria. Am. Soc. Mcrobiol 156 (2002).
   Google Scholar
• Cottagnoud P, Tauber MG. Fluoroquinolones in the treatment of meningitis. Cutr Infect. Dis. Rep. 5,
   Google Scholar
• Shinohara YT, Tasker SA, Wallace MR, Couch KE, Olson PE. What is the risk of
   Google Scholar
• Ortiz-De-Saracho J, Pantoja L, Romero MJ, Lopez R. Moxifloxacin-induced 329–336 (2003).
   Google Scholar
• Ostergaard C, Sorensen TK, Knudsen JD, Frimodt-Moller N. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimiavb. Agents Chemother. 42, 1706–1712 (1998).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Cerrato V, McCoig CC, Saavedra J, et al. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Antimicrob. Agents Chemother. 47,211–215 (2003).
   PubMed Web of Science ®Google Scholar
• Mather R, Karenchak LM, Romanowski EG, Kowalski RR Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am. J Ophthalmol 133,463–466 (2002).
   PubMed Web of Science ®Google Scholar
• Garcia-Saenz MC, Arias-Puente A, Fresnadillo-Martinez MJ, Carrasco-Font C. Human aqueous humor levels of oral ciprofloxacin, levofloxacin and moxifloxacin. J Cataract Refract. Surg. 27,1969–1974 (2001).
   PubMed Web of Science ®Google Scholar
• Hoogkamp-Korstanje JA, Roelofs-Willemse J. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J Antimicrob. Chemother. 45,31–39 (2000).
   PubMed Web of Science ®Google Scholar
• •A discussion of the activity against Gram-positive organisms.
   Google Scholar
• Hoppe JE, Dalhoff A, Pfrunder D. In vitro susceptibilities of Bordetella pertussis and Boirletella parapertussis to BAY 12-8039, trovafloxacin and ciprofloxacin. Antimicrob. Agents Chemother. 42,1868 (1998).
   PubMed Web of Science ®Google Scholar
• Di Caro S, Ojetti V, Zocco MA, etal. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther. 16, 527–532 (2002).
   PubMed Web of Science ®Google Scholar
• Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43,1756–1758 (1999).
   Web of Science ®Google Scholar
• Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33\(Suppl. 3), S147-156 (2001).
   PubMedGoogle Scholar
• Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumordae. Antimicrob. Agents Chemother. 45,433–438 (2001).
   PubMed Web of Science ®Google Scholar
• Iannini PB, Mandell LA. An updated safety profile of moxifloxacin. Chemother. 14 (Suppl. 2), 29–34 (2002).
   Google Scholar
• Man I, Murphy J, Ferguson J. Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. J Antimicrob. Chemother. 43(Suppl. B), 77–82 (1999).
   PubMedGoogle Scholar
• Schmuck G, Schurmann A, Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob. Agents Chemother. 42, 1831–1836 (1998).
   PubMed Web of Science ®Google Scholar
• Carbon C. Comparison of side effects of levofloxacin versus other fluoroquinolones. Chemotherapy47(Suppl. 3), 9–14 (2001); discussion 44–48 (2001).
   Google Scholar
• Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mal Pharmacol 59,122–126 (2001).
   PubMed Web of Science ®Google Scholar
• Iannini PB, Kubin R, Reiter C, Tillotson G. Reassuring safety profile of moxifloxacin. Clin. Infect. Dis. 32, 1112–1114 (2001).
   PubMed Web of Science ®Google Scholar
• Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 289, 2120–2127 (2003).
   PubMed Web of Science ®Google Scholar
• Baden LR, Horowitz G, Jacoby H, Eliopoulos GM. Quinolones and false-positive urine screening for opiates by immunoassay technology. JAIVIA 286, 3115–3119 (2001).
   PubMed Web of Science ®Google Scholar
• Van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BE Med 324,1306–1307 (2002).
   PubMed Web of Science ®Google Scholar
• Chhajed PN, Plit ML, Hopkins PM, Malouf MA, Glanville AR. Achilles tendon disease in lung transplant recipients: association with ciprofloxacin. Eur. Respir. J. 19,469–471 (2002).
   PubMed Web of Science ®Google Scholar
• Gabutti L, Stoller R, Marti HP. [Fluoroquinolones as etiology of tendinopathy]. Ther. Umsch 55,558–561 (1998).
   PubMedGoogle Scholar
• Aros C, Flores C, Mezzano S. [Achilles tendinitis associated to levofloxacin: report of 4 cases]. Rev Med. Child 130, 1277-1281 (2002). Clostridium difficile diarrhea. Ann. Pharmacother. 37,452–453 (2003).
   Google Scholar
• Stass H, Kubitza D. Profile of moxifloxacin drug interactions. Clin. Infect. Dis. 32\(Suppl. 1), S47-S50 (2001).
   PubMedGoogle Scholar
• Andriole VT, Haverstock D, Choudhri S, Church D. Safety of moxifloxacin (MXF) in the elderly. Am. Soc. 11/liavbiol. 348 (2002).
   Google Scholar
• Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging20, 289–302 (2003).
   Google Scholar
• Stass H, Bottcher ME, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. Clin. Pharmacokinet. 40\(Suppl. 1), 39–48 (2001).
   PubMedGoogle Scholar
• Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin. Pharmacokinet. 40\(Suppl. 1), 33–38 (2001).
   PubMedGoogle Scholar
• Stass H, Kubitza D. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans. Clin. Phatmacokinet. 40\(Suppl. 1), 57–62 (2001).
   PubMedGoogle Scholar
• Stass H, Schuhly U, Moller JG, Delesen H. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin. Pharmacokinet. 40\(Suppl. 1), 49–55 (2001).
   PubMedGoogle Scholar
• Stass H, Kubitza D. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone and theophylline. Clin. Pharmacokinet. 40\(Suppl. 1), 63–70 (2001).
   PubMed Web of Science ®Google Scholar
• Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. BE j Clin. Pharmacol 53,232–237 (2002).
   PubMed Web of Science ®Google Scholar
• Stass H, Dammer S, Kubitza D, Moeller J, Delesen H, Schaefers R. No dose adjustment is needed for patients undergoing hemodialysis (HD) receiving oral moxifloxacin (MFX). Am. Soc. Mcrobiol (2002).
   Google Scholar
• Stass H, Dammer S, Kubitza D, Moeller J, Delesen H, Schaefers R. Am. Soc. Mcrobiol (2002).
   Google Scholar
• Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin. Infect. Dis. 32\(Suppl. 1), S51-S63 (2001).
   Google Scholar
• Fogarty C, Choudhri S, Herrington J, et al. Moxifloxacin in the treatment of community-acquired pneumonia associated with drug-resistant Streptococcus pneumoniae. (2002) (Abstract 169).
   Google Scholar
• Goldstein EJ. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone and desfluoroquinolone therapeutic agents. Clin. Infect. Dis. 35, S106–S111 (2002).
   Web of Science ®Google Scholar
• Lachand AT, Lee BL, Padula AM, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl. Med 325,520–521 (1991).
   Web of Science ®Google Scholar
• Brueggemann AB, Coffman SL, Rhomberg P, et al Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimiavb. Agents Chemother. 46,680–688 (2002).
   PubMed Web of Science ®Google Scholar
• Parish LC, Routh HB, Miskin B, et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int. Clin. Pract. 54,497–503 (2000).
   PubMed Web of Science ®Google Scholar
• Leal del Rosal P, Martinez R, Fabian Gea. Efficacy and safety of moxifloxacin vs. cephalexin in the treatment of mild to moderate uncomplicated skin and soft tissue infections. 21st Internat. Congress Chemother. (1999) (Abstract no. P493).
   Google Scholar
• Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir. Merl. 94,337–344 (2000).
   PubMed Web of Science ®Google Scholar
• Arrieta J, Galgano A, Sakano E. Safety and efficacy of moxifloxacin (MFX) vs. Amoxicillin/Clavulanate (AMC) in the treatment of acute sinusitis. (2001).
   Google Scholar
• Klossek JM, Siegert R, Nikolaidis P, Arvis P, Leberre MA. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. Laryngol. Ora 117, 43–51 (2003).
   PubMed Web of Science ®Google Scholar
• Rakkar S, Roberts K, Towe BF, Flores SM, Heyd A, Warner J. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience. Int. Clin. Pract. 55, 309–315 (2001).
   PubMed Web of Science ®Google Scholar